Koshinski Asset Management Inc. Reduces Holdings in AstraZeneca PLC (NASDAQ:AZN)

Koshinski Asset Management Inc. lowered its holdings in AstraZeneca PLC (NASDAQ:AZN) by 21.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,147 shares of the company’s stock after selling 1,403 shares during the quarter. Koshinski Asset Management Inc.’s holdings in AstraZeneca were worth $347,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fairfield Bush & CO. purchased a new stake in AstraZeneca in the 2nd quarter worth approximately $25,000. ICA Group Wealth Management LLC purchased a new stake in AstraZeneca in the 4th quarter worth approximately $26,000. Anchor Investment Management LLC purchased a new stake in AstraZeneca in the 4th quarter worth approximately $26,000. Parkside Financial Bank & Trust lifted its holdings in AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after buying an additional 390 shares during the period. Finally, Compagnie Lombard Odier SCmA purchased a new stake in AstraZeneca in the 4th quarter worth approximately $27,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HSBC started coverage on AstraZeneca in a report on Monday, December 18th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Morgan Stanley assumed coverage on AstraZeneca in a research note on Tuesday, January 23rd. They issued an “overweight” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $80.00.

AstraZeneca Stock Down 0.3 %

AZN stock opened at $68.73 on Tuesday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $76.56. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.57. The firm has a market cap of $213.09 billion, a PE ratio of 35.80, a price-to-earnings-growth ratio of 1.26 and a beta of 0.50. The business has a 50 day moving average of $65.96 and a 200 day moving average of $65.83.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The company had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period last year, the business earned $0.69 EPS. On average, research analysts forecast that AstraZeneca PLC will post 4.02 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were issued a $0.965 dividend. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date was Thursday, February 22nd. This represents a dividend yield of 2.3%. AstraZeneca’s dividend payout ratio (DPR) is presently 100.52%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.